Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

Rhea-AI Summary

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference 2025. The conference will be held from March 10-12, 2025, at the W South Beach Hotel in Miami, FL.

The company, which specializes in treatments for bradykinin-mediated diseases including hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), will provide a live audio webcast of their presentation through their investor relations website. The recording will remain accessible for 30 days following the event.

ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that its management will participate in the Leerink Partners Global Healthcare Conference 2025, taking place from March 10-12, 2025, at the W South Beach Hotel in Miami, FL. Details are as follows:

Format:	Fireside Chat
Representative:	Berndt Modig, CEO of Pharvaris
Date & Time:	Monday, March 10, 9:20 a.m. ET

A live audio webcast will also be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. The audio replay will be available on Pharvaris’ website for 30 days following the presentation.

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy and placebo-like tolerability with the convenience of an oral therapy to prevent and treat HAE attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/.

FAQ

When and where is Pharvaris (PHVS) presenting at the Leerink Partners Conference 2025?

Pharvaris will present at the Leerink Partners Global Healthcare Conference from March 10-12, 2025, at the W South Beach Hotel in Miami, FL.

How can investors access Pharvaris's (PHVS) presentation at the Leerink Conference?

Investors can access the live audio webcast through Pharvaris's investor relations website at ir.pharvaris.com/news-events/events-presentations.

How long will Pharvaris's (PHVS) Leerink Conference presentation be available for replay?

The audio replay will be available on Pharvaris's website for 30 days following the presentation.

What medical conditions is Pharvaris (PHVS) developing treatments for?

Pharvaris is developing treatments for bradykinin-mediated diseases, specifically hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).